Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE3
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Cord Blood Expansion on Mesenchymal Stem Cells
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Trial of Pentostatin and Targeted Busulfan
- Status
- COMPLETED
- Phase
- PHASE2
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE3
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
- Status
- TERMINATED
- Phase
- PHASE2
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor
- Status
- WITHDRAWN
- Phase
- PHASE1
Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
- Status
- COMPLETED
- Phase
- NA
Study of Rituximab to Treat Chronic Renal Transplant Rejection
- Status
- COMPLETED
- Phase
- PHASE4
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2